Melissa Berhow

Peter Schmidt is a Clinical Assistant Professor specializing in Anesthesiology, Perioperative, and Pain Medicine, affiliated with Stanford Health Care in San Jose, CA. He holds board certifications in both Anesthesiology and Pain Medicine and completed his fellowship in Pain Management at Stanford University. Dr. Schmidt has an extensive educational background, including a medical degree from the University of Colorado School of Medicine and a residency at the University of Virginia Health System. His research contributions focus on postoperative pain management and opioid cessation, with several publications in reputable medical journals. Generated from the website

Dr. Boutrid specializes in Medical Oncology and Hematology and is board certified in Oncology and Internal Medicine. She completed her fellowship in Hematology and Medical Oncology at The Ohio State University Wexner Medical Center in Columbus, Ohio. During her training, Dr. Boutrid conducted clinical research focusing on breast cancer. She manages malignancies of solid organs and of the blood and bone marrow. Dr. Boutrid also manages benign blood disorders such as anemia, bleeding disorders and blood clots. She finds it a great privilege to be a physician and strives to provide compassionate, patient centered and science driven care. Dr. Boutrid provides care at the Stanford Medicine Cancer Center in South Bay.

I am a brain tumor neurosurgeon, treating patients with malignant and benign tumors, including gliomas, brain metastases, meningiomas, and schwannomas. I direct the Stanford Brain Tumor Center and the Stanford Brain Metastasis Consortium, collaborative unions of physicians and scientists looking to improve our understanding and treatment of brain tumors. My laboratory seeks greater understanding of the mechanisms driving tumorigenesis and disease progression in malignant brain tumors. We study how rare cancer cell populations survive and migrate in the brain, inadvertently supported by native brain cells. We develop novel cerebrospinal fluid-based biomarkers to track brain cancer treatment response, relapse, and neurotoxicity.